New Delhi, July 31 -- Sun Pharma announced its results for the quarter ended June 2025 (Q1FY26) today, July 31. The pharma stock's consolidated net profit fell 20 percent to Rs.2,279 crore in Q1FY26, dented by a one-time exceptional charge. It posted a net profit of Rs.2,835 crore in the same period last year. Sequentially, the profit rose 6 percent from Rs.2150 crore in the March quarter.

The consolidated revenue of the company rose over 9 percent to Rs.13,851 crore in the June 2025 quarter from Rs.12,653 crore in Q1FY25 in the quarter under review, driven by strong growth across key markets, including India, the US, and the Rest of World regions.

Sun Pharma's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for th...